TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Significant Increase in Short Interest

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 29,700 shares, a growth of 26.4% from the October 15th total of 23,500 shares. Based on an average daily volume of 13,700 shares, the days-to-cover ratio is currently 2.2 days. Approximately 0.3% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of TherapeuticsMD in a report on Friday. They set a “hold” rating on the stock.

Institutional Trading of TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission. 30.74% of the stock is currently owned by institutional investors.

TherapeuticsMD Stock Down 4.1 %

TXMD opened at $1.40 on Friday. TherapeuticsMD has a 52-week low of $1.36 and a 52-week high of $3.07. The firm’s fifty day simple moving average is $1.61 and its two-hundred day simple moving average is $1.78.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.